Tokyo Metropolitan Institute for Geriatrics and Gerontology at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Tokyo Metropolitan Institute for Geriatrics and Gerontology takes part in 3 sessions at CTAD 2026 in Boston. Its program centres on anti-amyloid therapy in Japanese practice. Its work covers post-marketing lecanemab results, ARIA patterns with donanemab and how uptake and eligibility changed over time.

OrganizationCTAD 2026 Attendance
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Updated Results from a Post-Marketing Observational Study of Lecanemab in Japan (P153)
Anti-amyloid and anti-tau therapies · Real-world data and access
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Thu Nov 19
7:15am–5:00pm

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Tokyo Metropolitan Institute for Geriatrics and Gerontology

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction